WAM
ABBV icon

Wakefield Asset Management’s AbbVie ABBV Stock Holding History

Wakefield Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.97M Buy
7,832
+10
+0.1% +$2.15K 0.44% 64
2026
Q1 		$1.7M Sell
7,822
-118
-1% -$26.2K 0.45% 63
2025
Q4 		$1.81M Sell
7,940
-289
-4% -$65.8K 0.49% 60
2025
Q3 		$1.91M Sell
8,229
-220
-3% -$44.8K 0.52% 55
2025
Q2 		$1.57M Sell
8,449
-228
-3% -$42.4K 0.44% 69
2025
Q1 		$1.82M Sell
8,677
-2,728
-24% -$530K 0.55% 52
2024
Q4 		$2.03M Buy
11,405
+65
+0.6% +$12K 0.68% 47
2024
Q3 		$2.24M Sell
11,340
-169
-1% -$31.5K 0.73% 44
2024
Q2 		$1.97M Sell
11,509
-5
-0% -$828 0.69% 45
2024
Q1 		$2.1M Buy
11,514
+768
+7% +$132K 0.73% 44
2023
Q4 		$1.67M Buy
+10,746
New +$1.57M 0.62% 55
2022
Q2 		– Sell
-2,398
Closed -$389K – 173
2022
Q1 		$389K Sell
2,398
-318
-12% -$46.2K 0.14% 142
2021
Q4 		$368K Sell
2,716
-20,352
-88% -$2.4M 0.13% 144
2021
Q3 		$2.49M Buy
23,068
+588
+3% +$67.2K 0.94% 38
2021
Q2 		$2.53M Sell
22,480
-69
-0.3% -$7.77K 0.96% 34
2021
Q1 		$2.44M Sell
22,549
-1,164
-5% -$125K 0.98% 31
2020
Q4 		$2.54M Sell
23,713
-2,131
-8% -$205K 1.07% 18
2020
Q3 		$2.26M Sell
25,844
-543
-2% -$51.1K 1.07% 34
2020
Q2 		$2.59M Sell
26,387
-2,112
-7% -$186K 1.24% 15
2020
Q1 		$2.17M Buy
28,499
+25,905
+999% +$2.21M 1.17% 23
2019
Q4 		$230K Buy
+2,594
New +$215K 0.1% 148
2019
Q3 		– Sell
-2,677
Closed -$195K – 149
2019
Q2 		$195K Buy
+2,677
New +$210K 0.08% 150

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wakefield Asset Management's ABBV Position: Q2 2026 in Review

Wakefield Asset Management increased its AbbVie (ABBV) stake by 0.13% in Q2 2026, buying an estimated $2.15K and bringing the position to 7,832 shares worth $1.97M. The position accounts for 0.44% of the portfolio, ranked #64.

Wakefield Asset Management first reported a position in ABBV in Q2 2019 and has held it in 22 quarters since. The position peaked at $2.59M in Q2 2020. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Wakefield Asset Management held 7,832 shares of AbbVie worth $1.97M as of Q2 2026.
  • Wakefield Asset Management bought 10 AbbVie shares in Q2 2026, an estimated $2.15K.
  • AbbVie made up 0.44% of Wakefield Asset Management's portfolio in Q2 2026, its #64 holding.
  • Wakefield Asset Management first reported a position in AbbVie in Q2 2019 and has held it in 22 quarters since.
  • Wakefield Asset Management's AbbVie position peaked at $2.59M in Q2 2020.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Wakefield Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.